Nuvectis Pharma Inc (NVCT)

$20.91 +1.83 (9.59%)
Market Cap 621.67M
Revenue (ttm) 0.00
Net Income (ttm) -26.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 217,800
Avg Vol 359,308
Day's Range N/A - N/A
Shares Out 32.58M
Stochastic %K 100%
Beta -0.26
Analysts Strong Sell
Price Target $34.00

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 614 3150
Address:
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, United States
UNLV
UNLV Aug. 19 at 3:46 PM
$NVCT $22 what becomes of the faint hearted? I wonder if faint hearted screwed up AI trades as badly botched NVCT trades were here. Think about that, I believe AI trades were botched tiny gains Insiders still deep NVCT GLSI haven’t sold a single share…WHAT ARE YOU DOING?
0 · Reply
UNLV
UNLV Aug. 17 at 1:30 PM
$NVCT last year’s lows had Charles loading, loading and reloading $5, $6, $7 and $8 shares. WHAT WERE YOU DOING? Charles was going all-in and I was tailing Charles GLSI $16 and now after last year’s debacle waiting on data you can join insider buying, my number 1 tool. Sold a fraction of NVCT to join this dance
0 · Reply
UNLV
UNLV Aug. 15 at 3:11 PM
$NVCT All you need to successfully trade small cap stocks are INSIDER TRADING tools, that’s it. End of story as other info comes in as NICE TO KNOW. Looking forward NVCT $100 remembering NXP900 trials expanding resistance and the multi billion dollar drug partners will have patients waiting without needs of huge sales teams that start off slow. MASSIVE PORTFOLIO POSITION
0 · Reply
UNLV
UNLV Aug. 15 at 2:55 PM
$NVCT just as I liked NVCT around insider buying also like $GLSI around insider buying. Sold small fraction of NVCT up 3x for me, to buy GLSI. Insider trading my NUMBER 1 indicator with small caps…everything changes, everything is connected PAY ATTENTION phase 3 drug and 250M market cap
2 · Reply
UNLV
UNLV Aug. 14 at 4:07 PM
$NVCT 600M market cap and best in class drug NXP100 in what’s expected to become 10B market. NXP200 looking best in class with only seeming downside paying royalties. NXP100 resistance combo as well but faint of heart, was faint of heart at lows $5, $6, $7…Sold a fraction to join insider buying of 200M market cap “GLSI”
0 · Reply
UNLV
UNLV Aug. 14 at 1:17 PM
$NVCT noise and chatter from faint of heart but I’m saying stock has superior prospects for 600M market cap Out of strength sold fraction of NVCT buying $GLSI 200M market cap alongside CEO buying GLSI = OVERWEIGHT NVCT = HUGE OVERWEIGHT Make your moves out of STRENGTH not out of weakness, moves out of weakness are always bad
0 · Reply
BioTrade2
BioTrade2 Aug. 14 at 10:46 AM
$NVCT look at the latest company presentation, total slides 24, nxp900 slides: 2 (buried at the end). You would think they would be eager to show upcoming data. Same thing happened last year when they got rid of the 800 program.
1 · Reply
buyandsold
buyandsold Aug. 13 at 6:04 PM
$NVCT Come down from 10% to 2% of my account today. I need to get a better understanding of the company's direction so I'm gonna wait for further updates. I have 26% in Abivax, 10% in Sarepta, 9% in Prothena, and 8% in Nectar. No other biotech plays. Well I do have some Seer, but that's not really a pure play. I'm just waiting for a buyout.
1 · Reply
BioTrade2
BioTrade2 Aug. 12 at 3:15 PM
$NVCT predicted 4! months earlier. My sixth sense says combo daya in q4 will underwhelm as well. Expect ORR under 25%.
2 · Reply
UNLV
UNLV Aug. 10 at 11:58 AM
$TENX My little action trade fell flat here but huge trade $NVCT stands strong. Nothing compares to tracking insider trading when evaluating small caps…WAKE UP
0 · Reply
Latest News on NVCT
Nuvectis Pharma Slides: Corporate presentation

Aug 10, 2026, 8:00 AM EDT - 9 days ago

Nuvectis Pharma Slides: Corporate presentation

Nuvectis Pharma price target raised to $34 from $22 at Lucid Capital

2026-08-05T10:11:18.000Z - 14 days ago

Nuvectis Pharma price target raised to $34 from $22 at Lucid Capital

Nuvectis Pharma Earnings release: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 15 days ago

Nuvectis Pharma Earnings release: Q2 2026

Nuvectis Pharma Quarterly report: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 15 days ago

Nuvectis Pharma Quarterly report: Q2 2026

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

Aug 4, 2026, 8:00 AM EDT - 15 days ago

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Jul 23, 2026, 9:00 AM EDT - 27 days ago

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Nuvectis Pharma receives marketing approval in China for ciprocopan

2026-07-23T11:45:23.000Z - 27 days ago

Nuvectis Pharma receives marketing approval in China for ciprocopan

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Jul 23, 2026, 7:30 AM EDT - 27 days ago

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Jul 14, 2026, 10:40 AM EDT - 5 weeks ago

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Nuvectis Pharma price target raised to $33 from $20 at Roth Capital

2026-07-06T01:00:06.000Z - 6 weeks ago

Nuvectis Pharma price target raised to $33 from $20 at Roth Capital

Nuvectis Pharma 5M share Spot Secondary priced at $20.00

2026-06-30T10:10:10.000Z - 7 weeks ago

Nuvectis Pharma 5M share Spot Secondary priced at $20.00

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Jun 29, 2026, 10:30 PM EDT - 7 weeks ago

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00

2026-06-29T21:50:11.000Z - 7 weeks ago

Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00

Nuvectis Pharma announces common stock offering, no amount given

2026-06-29T20:05:18.000Z - 7 weeks ago

Nuvectis Pharma announces common stock offering, no amount given

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Jun 29, 2026, 4:01 PM EDT - 7 weeks ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nuvectis Pharma price target raised to $22 from $18 at Lucid Capital

2026-06-22T17:42:15.000Z - 2 months ago

Nuvectis Pharma price target raised to $22 from $18 at Lucid Capital

Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright

2026-06-22T15:06:27.000Z - 2 months ago

Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright

Nuvectis gains two experimental drugs in licensing deal with China's Haisco

Jun 22, 2026, 8:34 AM EDT - 2 months ago

Nuvectis gains two experimental drugs in licensing deal with China's Haisco

Nuvectis Pharma Transcript: Status update

Jun 22, 2026, 8:30 AM EDT - 2 months ago

Nuvectis Pharma Transcript: Status update

Nuvectis Pharma Press release: Status update

Jun 22, 2026, 8:30 AM EDT - 2 months ago

Nuvectis Pharma Press release: Status update

Nuvectis Pharma announces license agreement with Haisco for two compounds

2026-06-22T12:01:43.000Z - 2 months ago

Nuvectis Pharma announces license agreement with Haisco for two compounds

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

Jun 22, 2026, 7:30 AM EDT - 2 months ago

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright

2026-06-12T16:12:33.000Z - 2 months ago

Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright

Nuvectis Pharma Transcript: AGM 2026

Jun 11, 2026, 10:00 AM EDT - 2 months ago

Nuvectis Pharma Transcript: AGM 2026

Nuvectis Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 9:00 AM EDT - 3 months ago

Nuvectis Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 14, 2026, 7:30 AM EDT - 3 months ago

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Nuvectis Pharma Slides: Corporate presentation

May 11, 2026, 7:00 AM EDT - 3 months ago

Nuvectis Pharma Slides: Corporate presentation

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

May 5, 2026, 7:30 AM EDT - 3 months ago

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Earnings release: Q1 2026

May 5, 2026, 7:30 AM EDT - 3 months ago

Nuvectis Pharma Earnings release: Q1 2026

Nuvectis Pharma Quarterly report: Q1 2026

May 5, 2026, 7:30 AM EDT - 3 months ago

Nuvectis Pharma Quarterly report: Q1 2026

Nuvectis Pharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Nuvectis Pharma Proxy statement: Proxy filing

Nuvectis Pharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Nuvectis Pharma Proxy statement: Proxy filing

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma management to meet with Maxim

2026-03-19T19:35:17.000Z - 5 months ago

Nuvectis Pharma management to meet with Maxim

Nuvectis Pharma Slides: Corporate presentation

Mar 13, 2026, 7:00 AM EDT - 5 months ago

Nuvectis Pharma Slides: Corporate presentation

Nuvectis Pharma files $150M mixed securities shelf

2026-02-13T21:05:11.000Z - 6 months ago

Nuvectis Pharma files $150M mixed securities shelf

Nuvectis Pharma Registration statement: Registration Filing

Feb 13, 2026, 7:00 AM EST - 6 months ago

Nuvectis Pharma Registration statement: Registration Filing

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Feb 11, 2026, 7:30 AM EST - 6 months ago

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Earnings release: Q4 2025

Feb 11, 2026, 7:00 AM EST - 6 months ago

Nuvectis Pharma Earnings release: Q4 2025

Nuvectis Pharma Annual report: Q4 2025

Feb 11, 2026, 7:00 AM EST - 6 months ago

Nuvectis Pharma Annual report: Q4 2025

Nuvectis Pharma announces initiation of Phase 1b study of NXP900

2025-12-17T12:13:26.000Z - 8 months ago

Nuvectis Pharma announces initiation of Phase 1b study of NXP900

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Dec 17, 2025, 7:00 AM EST - 8 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Nuvectis Pharma Transcript: KOL Event

Dec 2, 2025, 8:00 AM EST - 9 months ago

Nuvectis Pharma Transcript: KOL Event

Nuvectis Pharma Slides: KOL Event

Dec 2, 2025, 8:00 AM EST - 9 months ago

Nuvectis Pharma Slides: KOL Event

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nov 25, 2025, 8:00 AM EST - 9 months ago

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nuvectis Pharma Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 10 months ago

Nuvectis Pharma Earnings release: Q3 2025

Nuvectis Pharma Quarterly report: Q3 2025

Nov 4, 2025, 4:00 PM EST - 10 months ago

Nuvectis Pharma Quarterly report: Q3 2025

Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)

2025-11-04T13:20:44.000Z - 10 months ago

Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 8:15 AM EST - 10 months ago

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year

2025-11-04T12:36:25.000Z - 10 months ago

Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year

Nuvectis Pharma provides highlights from NXP900 poster presentations

2025-10-27T12:17:17.000Z - 10 months ago

Nuvectis Pharma provides highlights from NXP900 poster presentations

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 16, 2025, 8:00 AM EDT - 10 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nuvectis Pharma appoints Juan Sanchez to board of directors

2025-09-25T12:05:11.000Z - 11 months ago

Nuvectis Pharma appoints Juan Sanchez to board of directors

Nuvectis Pharma Slides: Corporate Presentation

Sep 5, 2025, 7:00 AM EDT - 1 year ago

Nuvectis Pharma Slides: Corporate Presentation

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 1 year ago

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Nuvectis Pharma Transcript: Status Update

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Transcript: Status Update

Nuvectis Pharma Press release: Status Update

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Press release: Status Update

Nuvectis Pharma initiates NXP900 program

2025-08-11T21:10:25.000Z - 1 year ago

Nuvectis Pharma initiates NXP900 program

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Nuvectis Pharma Quarterly report: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Quarterly report: Q2 2025

Nuvectis Pharma Earnings release: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Earnings release: Q2 2025

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 7:30 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

Jul 31, 2025, 7:45 AM EDT - 1 year ago

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

Nuvectis Pharma Slides: Corporate Presentation

Jun 13, 2025, 11:00 AM EDT - 1 year ago

Nuvectis Pharma Slides: Corporate Presentation

Nuvectis Pharma Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 10:30 AM EDT - 1 year ago

Nuvectis Pharma Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 16, 2025, 4:35 PM EDT - 1 year ago

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Quarterly report: Q1 2025

Nuvectis Pharma Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Earnings release: Q1 2025

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Apr 29, 2025, 4:25 PM EDT - 1 year ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Nuvectis Pharma Annual report: Q4 2024

Feb 25, 2025, 9:30 AM EST - 1 year ago

Nuvectis Pharma Annual report: Q4 2024

Nuvectis Pharma Earnings release: Q4 2024

Feb 25, 2025, 9:30 AM EST - 1 year ago

Nuvectis Pharma Earnings release: Q4 2024

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 7, 2025, 8:30 AM EST - 1 year ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 5, 2025, 9:01 AM EST - 1 year ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma Quarterly report: Q3 2024

Nuvectis Pharma Earnings release: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma Earnings release: Q3 2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Oct 28, 2024, 8:21 AM EDT - 1 year ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Nuvectis Pharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 12:00 PM EDT - 2 years ago

Nuvectis Pharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Nuvectis Pharma Quarterly report: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

Nuvectis Pharma Quarterly report: Q2 2024

Nuvectis Pharma Earnings release: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

Nuvectis Pharma Earnings release: Q2 2024

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 6, 2024, 8:28 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 16, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Quarterly report: Q1 2024

Nuvectis Pharma Earnings release: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Earnings release: Q1 2024

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma Slides: Corporate Presentation

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Slides: Corporate Presentation

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Nuvectis Pharma Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Nuvectis Pharma Earnings release: Q4 2023

Nuvectis Pharma Annual report: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Nuvectis Pharma Annual report: Q4 2023

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:32 AM EST - 2 years ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 8, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q3 2023

Nov 8, 2023, 7:00 AM EST - 3 years ago

Nuvectis Pharma Quarterly report: Q3 2023

Nuvectis Pharma Earnings release: Q3 2023

Nov 8, 2023, 7:00 AM EST - 3 years ago

Nuvectis Pharma Earnings release: Q3 2023

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 25, 2023, 7:30 PM EDT - 3 years ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 21, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Nuvectis Pharma Transcript: Status Update

Sep 14, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Transcript: Status Update

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Sep 6, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 9, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Quarterly report: Q2 2023

Nuvectis Pharma Earnings release: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Earnings release: Q2 2023

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

May 10, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

UNLV
UNLV Aug. 19 at 3:46 PM
$NVCT $22 what becomes of the faint hearted? I wonder if faint hearted screwed up AI trades as badly botched NVCT trades were here. Think about that, I believe AI trades were botched tiny gains Insiders still deep NVCT GLSI haven’t sold a single share…WHAT ARE YOU DOING?
0 · Reply
UNLV
UNLV Aug. 17 at 1:30 PM
$NVCT last year’s lows had Charles loading, loading and reloading $5, $6, $7 and $8 shares. WHAT WERE YOU DOING? Charles was going all-in and I was tailing Charles GLSI $16 and now after last year’s debacle waiting on data you can join insider buying, my number 1 tool. Sold a fraction of NVCT to join this dance
0 · Reply
UNLV
UNLV Aug. 15 at 3:11 PM
$NVCT All you need to successfully trade small cap stocks are INSIDER TRADING tools, that’s it. End of story as other info comes in as NICE TO KNOW. Looking forward NVCT $100 remembering NXP900 trials expanding resistance and the multi billion dollar drug partners will have patients waiting without needs of huge sales teams that start off slow. MASSIVE PORTFOLIO POSITION
0 · Reply
UNLV
UNLV Aug. 15 at 2:55 PM
$NVCT just as I liked NVCT around insider buying also like $GLSI around insider buying. Sold small fraction of NVCT up 3x for me, to buy GLSI. Insider trading my NUMBER 1 indicator with small caps…everything changes, everything is connected PAY ATTENTION phase 3 drug and 250M market cap
2 · Reply
UNLV
UNLV Aug. 14 at 4:07 PM
$NVCT 600M market cap and best in class drug NXP100 in what’s expected to become 10B market. NXP200 looking best in class with only seeming downside paying royalties. NXP100 resistance combo as well but faint of heart, was faint of heart at lows $5, $6, $7…Sold a fraction to join insider buying of 200M market cap “GLSI”
0 · Reply
UNLV
UNLV Aug. 14 at 1:17 PM
$NVCT noise and chatter from faint of heart but I’m saying stock has superior prospects for 600M market cap Out of strength sold fraction of NVCT buying $GLSI 200M market cap alongside CEO buying GLSI = OVERWEIGHT NVCT = HUGE OVERWEIGHT Make your moves out of STRENGTH not out of weakness, moves out of weakness are always bad
0 · Reply
BioTrade2
BioTrade2 Aug. 14 at 10:46 AM
$NVCT look at the latest company presentation, total slides 24, nxp900 slides: 2 (buried at the end). You would think they would be eager to show upcoming data. Same thing happened last year when they got rid of the 800 program.
1 · Reply
buyandsold
buyandsold Aug. 13 at 6:04 PM
$NVCT Come down from 10% to 2% of my account today. I need to get a better understanding of the company's direction so I'm gonna wait for further updates. I have 26% in Abivax, 10% in Sarepta, 9% in Prothena, and 8% in Nectar. No other biotech plays. Well I do have some Seer, but that's not really a pure play. I'm just waiting for a buyout.
1 · Reply
BioTrade2
BioTrade2 Aug. 12 at 3:15 PM
$NVCT predicted 4! months earlier. My sixth sense says combo daya in q4 will underwhelm as well. Expect ORR under 25%.
2 · Reply
UNLV
UNLV Aug. 10 at 11:58 AM
$TENX My little action trade fell flat here but huge trade $NVCT stands strong. Nothing compares to tracking insider trading when evaluating small caps…WAKE UP
0 · Reply
UNLV
UNLV Aug. 7 at 3:58 PM
$NVCT NO exception!! Executing option strategies on NVCT have to be done Limit orders for best price and try to stretch/bid the best possible prices Properly done returns can rival Warren Buffett’s option strategy 👀
0 · Reply
UNLV
UNLV Aug. 7 at 3:44 PM
$NVCT I like naked puts with 17.5 strike. Keep premiums if stock trades above 17.5 or exercise options and sell covered covered calls if stock trades lower Waiting on NXP900 data didn’t work for the crowd and most of what I’m seeing “StockTwits and X” is haphazard
0 · Reply
buyandsold
buyandsold Aug. 5 at 3:45 PM
$NVCT To my position today I used to have a 3.5 times bigger allocation to this stock and all my trims have been around 20. I missed the heady heights of 28 but there you go. They seem to have made some very competent moves to sustain the company but honestly if we get to above 25, I'll probably exit for other opportunities. If not I'll just wait for the next catalyst and see.
1 · Reply
StocktwitsNews
StocktwitsNews Aug. 4 at 5:50 PM
NVCT Q2 2026 Earnings Summary $NVCT https://stocktwits.com/news/earnings/earnings/nvct-q2-2026-earnings-summary/cZo5qwgRJ4J
0 · Reply
BioTrade2
BioTrade2 Aug. 4 at 3:59 PM
$NVCT ha, no wonder they raised at $20, with stock being at $30. 900 is a dud similar to 800. I will HODL, going down with the ship. At least I’m not going to lose as much as the insiders.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 4 at 1:45 PM
$NVCT Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.30
0 · Reply
UNLV
UNLV Aug. 4 at 1:07 PM
$NVCT on a scale 0-10 maybe 6 is right. Assuming only NXP900 resistance therapies have promise
0 · Reply
AmateurHourGR
AmateurHourGR Aug. 4 at 12:28 PM
$NVCT So much for NXP900 being the big catalyst. There goes that....
0 · Reply
Ravion_News_Filter
Ravion_News_Filter Aug. 4 at 12:22 PM
$NVCT · $CHGCF 🤝 Nuvectis Pharma, Inc. completed an in-licensing agreement with Haisco Pharmaceutical Group for ex-China rights to compounds NXP100 and NXP200, transforming Nuvectis into a late-stage clinical development organization. Prioritized by relevance
0 · Reply
WallStWireAds
WallStWireAds Aug. 4 at 12:03 PM
$NVCT https://www.globenewswire.com/news-release/2026/08/04/3338215/0/en/Nuvectis-Pharma-Reports-Second-Quarter-2026-Financial-Results-and-
0 · Reply
kkorotney
kkorotney Aug. 4 at 4:21 AM
$NVCT feeling this is going to be a good week.
0 · Reply
BioTrade2
BioTrade2 Jul. 30 at 5:39 PM
$NVCT yahoo finance shows earnings on Aug 4, Fidelity shows Aug 3. Can you check and tell me what your brokerage shows? @UNLV @buyandsold anyone else?
1 · Reply